Literature DB >> 27178670

Short-term Prognosis and Current Management of Syncopal Patients at Intermediate Risk: Results from the IRiS (Intermediate-Risk Syncope) Study.

Filippo Numeroso1, Gianluigi Mossini1, Michela Giovanelli2, Giuseppe Lippi3, Gianfranco Cervellin1.   

Abstract

OBJECTIVES: Despite guidelines, admission rates and expenditures for syncope remain high. This may be caused by an imprecise definition of cardiovascular disease considered at risk and an overestimation of the role of comorbidities and advanced age. In a cohort of patients with undetermined syncope, we prospectively compared the short-term prognosis of patients at intermediate risk (i.e., with stable heart diseases or comorbidities, of any age) versus those at high risk for cardiogenic syncope and identified factors associated with serious events. Secondarily, we analyzed the current management of intermediate-risk patients.
METHODS: In a cohort of patients with undetermined syncope, we analyzed personal data, the presence of stable heart diseases or comorbidities, destination, length of hospitalization, incidence of serious events at 30 days, and costs.
RESULTS: In a 6-month period, 347 patients (185 male and 162 female, age 72.8 years) with undetermined syncope were enrolled, 250 at intermediate risk and 97 at high risk. Intermediate-risk patients were younger, with less frequent comorbidities and with a drastically lower incidence of serious events (0.8% vs. 27.8%, p < 0.001). Risk factors for cardiogenic syncope were the unique variable associated with serious events. Intermediate-risk patients were mostly admitted (62.8%) in an ordinary ward or into an emergency department observation unit; in the case of ordinary admission we observed a mean prolonged hospitalization (8.8 days), elevated costs ($270,183), and a high rate of unexplained syncope (51%).
CONCLUSIONS: According to the results of this study, the authors believe that intermediate-risk patients could be safely discharged, with potentially significant costs saving. In prognostic stratification, priority is to seek risk factors for cardiogenic syncope while advanced age, stable heart diseases, or comorbidities likely lead to inappropriate hospitalization.
© 2016 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Year:  2016        PMID: 27178670     DOI: 10.1111/acem.13013

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  5 in total

1.  Syncope Risk Stratification in the Emergency Department: Another Step Forward.

Authors:  Bret A Nicks; Brian C Hiestand
Journal:  Acad Emerg Med       Date:  2016-08       Impact factor: 3.451

Review 2.  Outcomes in syncope research: a systematic review and critical appraisal.

Authors:  Monica Solbiati; Viviana Bozzano; Franca Barbic; Giovanni Casazza; Franca Dipaola; James V Quinn; Matthew J Reed; Robert S Sheldon; Win-Kuang Shen; Benjamin C Sun; Venkatesh Thiruganasambandamoorthy; Raffaello Furlan; Giorgio Costantino
Journal:  Intern Emerg Med       Date:  2018-01-18       Impact factor: 3.397

3.  Recurrent syncope is not an independent risk predictor for future syncopal events or adverse outcomes.

Authors:  Anna Marie Chang; Judd E Hollander; Erica Su; Robert E Weiss; Annick N Yagapen; Susan E Malveau; David H Adler; Aveh Bastani; Christopher W Baugh; Jeffrey M Caterino; Carol L Clark; Deborah B Diercks; Bret A Nicks; Daniel K Nishijima; Manish N Shah; Kirk A Stiffler; Alan B Storrow; Scott T Wilber; Benjamin C Sun
Journal:  Am J Emerg Med       Date:  2018-08-24       Impact factor: 2.469

Review 4.  Role of emergency department observation units in the management of patients with unexplained syncope: a critical review and meta-analysis.

Authors:  Filippo Numeroso; Gianluigi Mossini; Giuseppe Lippi; Gianfranco Cervellin
Journal:  Clin Exp Emerg Med       Date:  2017-12-30

Review 5.  Predictors of Short-Term Outcomes after Syncope: A Systematic Review and Meta-Analysis.

Authors:  Thomas A Gibson; Robert E Weiss; Benjamin C Sun
Journal:  West J Emerg Med       Date:  2018-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.